Table 2.
Comparison of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30), Breast Cancer 23 items (EORTC QLQ-BR23), and European Quality of Life 5 Dimensions 3 Level (EQ 5D 3L) scores of participants at baseline and at 12 months.
| Baseline | 12 Months | Changes | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| EORTC QLQ-C30 | N | Mean | SD | N | Mean | SD | N | Mean | SD | p |
| Functioning | ||||||||||
| Physical functioning | 226 | 83.16 | 14.04 | 214 | 86.95 | 12.48 | 213 | 3.8 | 10.0 | 0.003 |
| Role functioning | 224 | 80.88 | 21.99 | 212 | 86.79 | 17.58 | 210 | 5.9 | 21.3 | 0.002 |
| Emotional functioning | 226 | 76.13 | 20.59 | 215 | 78.33 | 18.96 | 214 | 1.9 | 19.2 | 0.239 |
| Cognitive functioning | 225 | 82.37 | 21.14 | 213 | 81.77 | 18.25 | 211 | −0.8 | 17.9 | 0.750 |
| Social functioning | 226 | 78.25 | 24.84 | 216 | 88.12 | 17.02 | 215 | 9.5 | 22.9 | <0.001 |
| Symptoms | ||||||||||
| Fatigue | 227 | 31.68 | 22.28 | 213 | 24.15 | 18.00 | 213 | −8.0 | 21.9 | <0.001 |
| Nausea and vomiting | 226 | 7.15 | 12.93 | 214 | 4.36 | 10.79 | 213 | −2.7 | 12.9 | 0.015 |
| Pain | 226 | 22.58 | 21.42 | 213 | 19.33 | 19.51 | 212 | −3.2 | 19.5 | 0.099 |
| Dyspnoea | 226 | 18.73 | 22.40 | 215 | 12.25 | 19.06 | 214 | −6.1 | 23.5 | 0.001 |
| Insomnia | 226 | 28.17 | 27.36 | 211 | 27.01 | 26.87 | 210 | −0.6 | 28.0 | 0.656 |
| Appetite loss | 227 | 7.20 | 17.24 | 216 | 4.94 | 13.50 | 216 | −2.2 | 19.7 | 0.127 |
| Constipation | 200 | 15.00 | 22.85 | 208 | 10.74 | 20.65 | 185 | −4.0 | 24.7 | 0.049 |
| Diarrhoea | 225 | 8.15 | 16.30 | 216 | 6.48 | 14.70 | 215 | −1.6 | 19.3 | 0.261 |
| Financial | 224 | 16.96 | 25.25 | 216 | 11.42 | 20.67 | 213 | −5.8 | 24.3 | 0.012 |
| Global Health Status/QoL | 225 | 63.89 | 21.30 | 216 | 70.87 | 17.90 | 214 | 7.0 | 20.4 | <0.001 |
| EORTC QLQ-BR23 | ||||||||||
| Functioning | ||||||||||
| Body image | 226 | 65.04 | 29.98 | 215 | 77.17 | 23.39 | 214 | 11.8 | 24.0 | <0.001 |
| Sexual functioning | 222 | 81.83 | 22.09 | 213 | 77.0 | 22.73 | 208 | −4.2 | 21.0 | 0.025 |
| Future perspective | 226 | 45.58 | 34.61 | 216 | 57.10 | 30.00 | 215 | 11.0 | 29.3 | <0.001 |
| Symptoms | ||||||||||
| Systematic therapy side effects | 225 | 24.06 | 18.35 | 214 | 16.07 | 11.60 | 213 | −7.7 | 15.4 | <0.001 |
| Breast symptoms | 224 | 20.65 | 18.71 | 215 | 15.97 | 15.12 | 212 | −4.8 | 18.8 | 0.004 |
| Arm symptoms | 224 | 20.39 | 19.16 | 214 | 17.44 | 18.59 | 211 | −2.8 | 17.0 | 0.104 |
| EQ-5D-3L | ||||||||||
| EQ INDEX SCORE | 225 | 0.88 | 0.10 | 219 | 0.88 | 0.11 | 218 | 0.01 | 0.09 | 0.237 |
| EQ VAS SCORE | 222 | 68.61 | 15.91 | 222 | 74.55 | 15.30 | 218 | 5.80 | 14.82 | 0.001 |
SD: standard deviation; Changes: mean changes from baseline to 12 months; QoL: quality of life; VAS: visual analogue scale. Bold data indicate statistically significant p-values (significance p < 0.05).